Certriad is an investigational compound under joint development by AstraZeneca and Abbott for the treatment of mixed dyslipidemia.
Abbott and AstraZeneca’s decision was made after careful consideration of the Complete Response Letter (CRL) issued by the US Food and Drug Administration (FD).
Reportedly, the CRL for the Certriad new drug application (NDA) was issued on 30 March 2010.
AstraZeneca said that it will continue to focus on other development priorities both within and outside of the cardiovascular disease therapeutic area.